Larry Ellingson
Director/Board Member chez KNOW LABS, INC.
Fortune : 10 183 $ au 31/03/2024
Profil
Larry K.
Ellingson is the founder of the Diabetes Leadership Council, which was founded in 2013.
He held the title of Vice Chairman-Global Initiatives at the council.
Mr. Ellingson's current job(s) include being an Independent Director at Know Labs, Inc. since 2019, a Director at North Dakota State University, a Director at the Academy of Nutrition & Dietetics, a Director at the Nurse Practitioner Healthcare Foundation, and a Member of The Pinnacle Society.
Mr. Ellingson's former job(s) include being the Chairman & Chief Executive Officer of Protemix Corp.
Ltd.
from 2009 to 2010, the Chairman, President & Chief Executive Officer of Islet Sciences, Inc. in 2015 and 2016, and a Director of Pharmaceutical New Product Planning at Eli Lilly & Co. from 1971 to 2001.
He was also a Director at the American Diabetes Association and a Member of the International Diabetes Federation.
Mr. Ellingson's education history includes an MBA from Babson College and an undergraduate degree from North Dakota State University, which was conferred in 1969.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
KNOW LABS, INC.
0,02% | 08/02/2024 | 16 164 ( 0,02% ) | 10 183 $ | 31/03/2024 |
Postes actifs de Larry Ellingson
| Sociétés | Poste | Début |
|---|---|---|
| KNOW LABS, INC. | Director/Board Member | 03/11/2023 |
| North Dakota State University | Director/Board Member | - |
Academy of Nutrition & Dietetics
 Academy of Nutrition & Dietetics Miscellaneous Commercial ServicesCommercial Services Academy of Nutrition & Dietetics operates as food and nutrition professionals. The non-profit company is based in Chicago, IL. Wylecia Wiggs Harris has been the CEO of the company since 2023. | Director/Board Member | - |
| Nurse Practitioner Healthcare Foundation | Director/Board Member | - |
The Pinnacle Society
 The Pinnacle Society Miscellaneous Commercial ServicesCommercial Services The Pinnacle Society engages in recruitments, direct placement and executive search. The company was founded in 1989 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
Anciens postes connus de Larry Ellingson
| Sociétés | Poste | Fin |
|---|---|---|
| ISLET SCIENCES INC | Chief Executive Officer | 01/02/2016 |
International Diabetes Federation
 International Diabetes Federation Miscellaneous Commercial ServicesCommercial Services The International Diabetes Federation (IDF) is an umbrella organization of over 240 national diabetes associations in 160 countries and territories. The private company is based in Brussels, Belgium. The mission of IDF is to promote diabetes care, prevention, and a cure worldwide. IDF advocates for people with diabetes and works towards its mission by collaborating with national diabetes associations, healthcare professionals, and policymakers. Founded in 1950, IDF represents the interests of the growing number of people with diabetes and those at risk. | Corporate Officer/Principal | 01/01/2012 |
Protemix Corp. Ltd.
 Protemix Corp. Ltd. Pharmaceuticals: MajorHealth Technology Protemix Corporation is a biopharmaceutical company that discovers, develops and commercializes novel therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and their complications. Through cost-effective research in New Zealand, the company has assembled a pipeline of novel and innovative compounds, The most advanced compound is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix has assembled a pipeline of novel and innovative compounds, the most advanced of which is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix’s discovery capabilities capitalize on the 30-year research expertise of the company’s founder, Professor Garth Cooper, a widely recognized expert in the field of peptide hormones, metabolic regulation and diabetes. The company’s discovery efforts are grounded in a detailed understanding of the potential mechanisms underlying diabetes and its complications, and have resulted in a pipeline of drug candidates that intervene at specific, well-defined disease targets to rebalance and renormalize key systems, thus enabling tissue repair and regeneration. Protemix’s lead compound, PX811019, is an orally active molecule that has shown the ability to reverse heart failure based on preclinical diabetic models and significantly reduced left ventricular hypertrophy in human clinic trials. Protemix studies suggest that PX811019 works by rebalancing abnormal copper accumulation in heart muscle, significantly improving cardiac structure and function without lowering blood glucose. The company has received Fast Track status for this compound from the U.S. Food and Drug Administration. The company has a second compound, PX811013, in late preclinical development for the treatment of both alcohol-mediated and non-alcoholic liver damage. The Protemix pipeline also includes six preclinical discovery programs addressing significant market opportunities. Protemix has its commercialization activities and late stage clinical trials driven from San Diego, California with administrative offices in Auckland, New Zealand and research laboratories at the University of Auckland. The company, founded in 1999, is privately held. | Chairman | 24/03/2009 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/05/2001 |
| ░░░░░░░░ ░░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░ | - |
Formation de Larry Ellingson
| Babson College | Masters Business Admin |
| North Dakota State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| KNOW LABS, INC. | Electronic Technology |
| Entreprise privées | 7 |
|---|---|
Protemix Corp. Ltd.
Protemix Corp. Ltd. Pharmaceuticals: MajorHealth Technology Protemix Corporation is a biopharmaceutical company that discovers, develops and commercializes novel therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and their complications. Through cost-effective research in New Zealand, the company has assembled a pipeline of novel and innovative compounds, The most advanced compound is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix has assembled a pipeline of novel and innovative compounds, the most advanced of which is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix’s discovery capabilities capitalize on the 30-year research expertise of the company’s founder, Professor Garth Cooper, a widely recognized expert in the field of peptide hormones, metabolic regulation and diabetes. The company’s discovery efforts are grounded in a detailed understanding of the potential mechanisms underlying diabetes and its complications, and have resulted in a pipeline of drug candidates that intervene at specific, well-defined disease targets to rebalance and renormalize key systems, thus enabling tissue repair and regeneration. Protemix’s lead compound, PX811019, is an orally active molecule that has shown the ability to reverse heart failure based on preclinical diabetic models and significantly reduced left ventricular hypertrophy in human clinic trials. Protemix studies suggest that PX811019 works by rebalancing abnormal copper accumulation in heart muscle, significantly improving cardiac structure and function without lowering blood glucose. The company has received Fast Track status for this compound from the U.S. Food and Drug Administration. The company has a second compound, PX811013, in late preclinical development for the treatment of both alcohol-mediated and non-alcoholic liver damage. The Protemix pipeline also includes six preclinical discovery programs addressing significant market opportunities. Protemix has its commercialization activities and late stage clinical trials driven from San Diego, California with administrative offices in Auckland, New Zealand and research laboratories at the University of Auckland. The company, founded in 1999, is privately held. | Health Technology |
International Diabetes Federation
International Diabetes Federation Miscellaneous Commercial ServicesCommercial Services The International Diabetes Federation (IDF) is an umbrella organization of over 240 national diabetes associations in 160 countries and territories. The private company is based in Brussels, Belgium. The mission of IDF is to promote diabetes care, prevention, and a cure worldwide. IDF advocates for people with diabetes and works towards its mission by collaborating with national diabetes associations, healthcare professionals, and policymakers. Founded in 1950, IDF represents the interests of the growing number of people with diabetes and those at risk. | Commercial Services |
American Diabetes Association
 American Diabetes Association Miscellaneous Commercial ServicesCommercial Services American Diabetes Association provides diabetes related medical services. It funds research, publishes scientific findings, provides information and other services to people with diabetes, their families, health professionals and the public. The company was founded in 1940 and is headquartered in Alexandria, VA. | Commercial Services |
The Pinnacle Society
The Pinnacle Society Miscellaneous Commercial ServicesCommercial Services The Pinnacle Society engages in recruitments, direct placement and executive search. The company was founded in 1989 and is headquartered in Boston, MA. | Commercial Services |
Academy of Nutrition & Dietetics
Academy of Nutrition & Dietetics Miscellaneous Commercial ServicesCommercial Services Academy of Nutrition & Dietetics operates as food and nutrition professionals. The non-profit company is based in Chicago, IL. Wylecia Wiggs Harris has been the CEO of the company since 2023. | Commercial Services |
Islet Sciences, Inc.
 Islet Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Islet Sciences, Inc. is a biotechnology company, which engaged in the research, development, and commercialization of new medicines and technologies for the treatment of metabolic diseases. Its product portfolio included small molecule therapeutics, islet cell transplantation, and a molecular diagnostic to detect the onset of diabetes. The company was founded on September 14, 1994 and is headquartered in Yorba Linda, CA. | Commercial Services |
| Nurse Practitioner Healthcare Foundation |
